ArticleBiomedica : revista del Instituto Nacional de Salud2025
Botulinum toxin treatment in a resource-limited setting: Experiences from a public institution in a developing country
Article in Biomedica : revista del Instituto Nacional de Salud, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Trends and off-label use of botulinum toxin type A in Chinese neurological practice from 2016 to 2023: a real-world study.Frontiers in pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction. Botulinum toxins have at least 30 therapeutic indications across different medical specialties. Some Latin American studies have described the experience of applying botulinum toxin in isolated clinical contexts. However, researchers have yet to provide comprehensive analysis about its use across diverse clinical indications. Objective. To classify the therapeutic use of botulinum toxin in a public health center in Bogotá, identifying the risks of pharmacological interactions and possible barriers related to its use. This knowledge will promote a better understanding of the indications, practices, and regulations regarding the use of the botulinum toxin in the Colombian context. Materials and methods. A cross-sectional study was conducted to analyze the use of botulinum toxin in a public institution in Bogotá, Colombia, applying the prescriptionindication methodology. Sociodemographic, clinical, and pharmacoepidemiologic data were extracted from medical records and the electronic prescription database Mi prescripción. A bivariate statistical analysis was performed using JAMOVI software, version 2.2.5. Results. A total of 197 patients received a prescription for botulinum toxin. Although the main indication was temporomandibular joint disorder, 70.6% of the prescriptions were classified under neurological conditions. In pediatric patients, the main indication was spastic cerebral palsy (90%). Most described clinical uses (92.4%) were aligned with the indications approved by the Instituto Nacional de Vigilancia de Medicamentos y Alimentos de Colombia. Risks of drug interactions were identified in 30.9% of the cases and were significantly associated with an anticholinergic load (p < 0.001). Conclusions. Botulinum toxin is used for multiple indications in multiple medical specialties. There is consistency between prescription and indication of the medication recommended by regulatory entities. Reviewing patient’s pharmacological history is essential before prescribing botulinum toxin to reduce the risk of drug interactions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.